Insight into the biomarkers as the novel anti-psoriatic drug discovery tool: A contemporary viewpoint

Current Drug Discovery Technologies

Volumn 9, Issue 1, 2012, Pages 48-62

  Rahman, Mahfoozur ^a   Ahmad, Mohammad Zaki ^a   Kazmi, Imran ^b   Akhter, Sohail ^c   Beg, Sarwar ^c   Gupta, Gaurav ^b   Afzal, Muhammad ^b   Saleem, Shakir ^c   Ahmad, Iqbal ^c   Shaharyar, Md Adil ^c   Ahmed, Farhan Jalees ^c   Anwar, Firoz ^b  

^a Dreamz College of Pharmacy   (India)

^b Siddhartha Institute of Pharmacy   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

Biological agents; Biomarkers; Drug targeting; Gene marker; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; ARACHIDONIC ACID; BASILIXIMAB; BRIAKINUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; DACLIZUMAB; DENILEUKIN DIFTITOX; EFALIZUMAB; EMBREL; ENZYME; ETANERCEPT; HLA ANTIGEN; INFLIXIMAB; MEDIMMUNE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE; PEPTIDE; PROTEIN CDC42; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; SIPLIZUMAB; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ABSENCE OF SIDE EFFECTS; APOPTOSIS; ARTHRALGIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILL; CORNEA CELL; COUGHING; CYTOKINE PRODUCTION; DIZZINESS; DNA DAMAGE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INDUCTION; FEVER; GENE; HEADACHE; HUMAN; INFLAMMATION; INJECTION SITE REACTION; LIPID PEROXIDATION; NAUSEA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PRURITUS; PSORIASIS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH PAIN; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

BIOLOGICAL MARKERS; DERMATOLOGIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; GENETIC MARKERS; HUMANS; PSORIASIS;

EID: 84858171449     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/157016312799304516     Document Type: Review

References (219)

1. Travis L, Weinberg JM. Medical backgrounder: psoriasis. Drugs Today 2002; 38: 847-65. (Pubitemid 36245174)
2. Lebwohl M: Psoriasis. Lancet 2003; 361: 1197-04.
3. Christophers E. Psoriasis epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20.
4. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients, beliefs and attitudes towards the disease. Br J Dermatol 1996; 135: 533-7. (Pubitemid 26340262)
5. International psoriasis council IPC) Psoriasis Review: Focus on Asia-pacific, May 2010.
6. Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokines network in psoriasis. Clin Dermatol 2007; 25: 568-73.
7. Lowes MA, Bowcock AM, Krueger, JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
8. Shim JS, Kwon YY, Han YS, Hwang JK. Inhibitory effect of panduratin A on UV-induced activation of mitogen-activated protein kinases (MAPKs) in dermal fibroblast cells. Planta Med 2008; 74: 1446-50.
9. Kim AL, Labasi JM, Zhu Y, et al. Role of p38 MAPK in UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. J Invest Dermatol 2005; 124: 1318-25. (Pubitemid 40847422)
10. Lin WJ, Norris DA, Achziger M, Kotzin BL, Tomkinson B. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol 2001; 117: 1546-53. (Pubitemid 34032786)
11. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155: 145-58. (Pubitemid 29318713)
12. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989: 281: 24-30. (Pubitemid 19064135)
13. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275: 181-9. (Pubitemid 13056614)
14. Morganroth GS, Chan LS, Weinstein GD, Voorhees JJ, Cooper KD. Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol 1991: 96: 333-40.
15. Berridge MJ. Lymphocyte activation in health and disease. Crit Rev Immunol 1997: 17: 155-178. (Pubitemid 27161350)
16. Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995; 15: 235-53. (Pubitemid 26259130)
17. Racke MK, Stuart RW. Targeting T cell costimulation in autoimmune disease. Expert Opin Ther Targets 2002; 6: 275-89. (Pubitemid 34662101)
18. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesionfree psoriatic skin is characterized by a T-helper type 1 cellmediated response. J Invest Dermatol 1993: 101: 701-05. (Pubitemid 23322027)
19. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999: 38: 241-251. (Pubitemid 29189627)
20. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines interferongamma, IL-2 and tumor necrosis factor-alpha defining TCI (cytotoxic T lymphocyte) and THI effector populations a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113: 752-9.
21. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol 1995; 105 (Suppl): 89S-94S.
22. Lebwohl M, Ali S. Treatment of psoriasis Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-98. (Pubitemid 32917240)
23. Lebwohl M, Ali S. Part 2: Treatment of psoriasis Systemic therapies. J Am Acad Dermatol 2001; 45: 649-61. (Pubitemid 33032559)
24. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5-21. (Pubitemid 351252710)
25. International psoriasis council (IPC) Psoriasis Review - December 2010 issue.
26. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The Impact of Psoriasis on Quality of Life. Results a 1998 Natl Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 2001; 137: 280-84. (Pubitemid 32240779)
27. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-83. (Pubitemid 29480408)
28. De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research a systematic literature review. Arch Dermatol 2002; 138: 1221-7. (Pubitemid 35025697)
29. Swanbeck G, Inerot A, Martinsson T, Wahlström J. A population genetic study of psoriasis. Br J Dermatol 1994; 131: 32-9. (Pubitemid 24234285)
30. Tagami H. Triggering factors. Clin Dermatol 1997; 15: 677-85. (Pubitemid 27411302)
31. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
32. de Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008; 35: 1443-8. (Pubitemid 352000801)
33. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004; 15: 1677-89. (Pubitemid 38822046)
34. Sander CS, Chang H, Hamm F, Elsner P, Thiele JJ. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol 2004; 43: 326-35. (Pubitemid 38714593)
35. Genova ML, Pich MM, Bernacchia A, et al. The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann N Y Acad Sci 2004; 1011: 86-100. (Pubitemid 38608395)
36. Babior BM. NADPH oxidase: an update. Blood 1999; 93: 1464-76. (Pubitemid 29102471)
37. Van Heerebeek L, Meischl C, Stooker W, Meijer CJ, Niessen HW, Roos D. NADPH oxidase(s) new source(s) of reactive oxygen species in the vascular system. J Clin Pathol 2002; 55: 561-68.
38. Kuhn H, Thiele BJ. The diversity of the lipoxygenase family many sequence data but little information on biological significance. FEBS Lett 1999; 449: 7-11. (Pubitemid 29182660)
39. Kuehl Jr FA, Egan RW. Prostaglandins arachidonic acid and inflammation. Science. 1980; 210: 978-84.
40. McCarthy S, Somayajulu M, Sikorska M, Borowy-Borowski H, Pandey S. Paraquat induces oxidative stress and neuronal cell death neuroprotection by water-soluble coenzyme Q10. Toxicol Appl Pharmacol 2004; 201: 21-31. (Pubitemid 39446323)
41. Leonard SS, Harris GK, Shi X. Metal-induced oxidative stress and signal transduction. Free Radic Biol Med 2004; 37: 1921-42. (Pubitemid 39491314)
42. Ogawa Y, Kobayashi T, Nishioka A, et al. Radiation-induced oxidative DNA damage, 8-oxoguanine, in human peripheral T cells. Int J Mol Med 2003; 11: 27-32.
43. Herrling T, Fuchs J, Rehberg J, Groth N. UV-induced free radicals in the skin detected by ESR spectroscopy and imaging using nitroxides. Free Radic Biol Med 2003; 35: 59-67. (Pubitemid 36782337)
44. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727- 41.
45. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000; 207: 77-86.
46. Bickers DR, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 2006; 126: 2565-75. (Pubitemid 44764040)
47. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome oxidants, myeloperoxidase and bacterial killing. Blood 1998; 92: 3007-17. (Pubitemid 28492304)
48. Trouba KJ, Hamadeh HK, Amin RP, Germolec DR. Oxidative stress and its role in skin disease. Antioxid Redox Signaling 2002; 4: 665-73. (Pubitemid 35001451)
49. Finkel T, Holbrook NJ. Oxidants oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.
50. Gilhar A, Ullmann Y, Kerner H, et al. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 2002; 119: 384-91. (Pubitemid 35001948)
51. Arenberger P, Kemény L, Süss R, Michel G, Peter RU, Ruzicka T. Interleukin-8 receptors in normal and psoriatic polymorphonuclear leukocytes. Acta Derm Venereol 1992; 72: 334-36.
52. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-43. (Pubitemid 41002916)
53. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005; 102: 19057-62. (Pubitemid 43049565)
54. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30. (Pubitemid 38076484)
55. Wang F, Lee E, Lowes MA, et al. Prominent production of IL-20 by CD68+/ CD11c+ myeloid-derived cells in psoriasis gene regulation and cellular effects. J Invest Dermatol 2006; 126: 1590-99.
56. Kemmett D, Symons JA, Colver GB, Duff GW. Serum-soluble interleukin 2 receptor in psoriasis failure to reflect clinical improvement. Acta Derm Venereol 1990; 70: 264-66.
57. Pietrzak AT, Zalewska A, Chodorowska G, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7-21.
58. Elder JT. IL-15 and psoriasis another genetic link to Th17. J Invest Dermatol 2007; 127: 2495-7. (Pubitemid 47585052)
59. Haider AS, Lowes MA, Suarez-Farinas M, et al. Identification of cellular pathways of type 1q Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180: 1913-20.
60. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol1998; 111: 645-9. (Pubitemid 28452327)
61. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999; 162: 494-502. (Pubitemid 29018959)
62. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 2000; 115: 81-7. (Pubitemid 30470196)
63. Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med 1993; 177: 1779-84. (Pubitemid 23146145)
64. Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86: 6367-71. (Pubitemid 19210653)
65. Finch PW, Murphy F, Cardinale I, Krueger JG. Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol 1997; 151: 1619-28. (Pubitemid 27527924)
66. Seternes OM, Mikalsen T, Johansen B, et al. Activation of MK5/PRAK by the typical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J 2004; 23: 4780-91. (Pubitemid 40069708)
67. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995; 20: 117-22.
68. Davis RJ, MAPKs new JNK expands the group. Trends Biochem Sci 1994; 19: 470-3. (Pubitemid 24342759)
69. Takahashi H, Ibe M, Nakamura S, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 2002; 30: 94-99. (Pubitemid 36159019)
70. Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005; 152: 37-42.
71. Yu XJ, Li CY, Dai HY, et al. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp Mol Pathol 2007; 83: 413-18.
72. Burgering BM, de Vries-Smits AM, Medema RH, van Weeren PC, Tertoolen LG, Bos JL. Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways. Mol Cell Biol 1993; 13: 7248-56. (Pubitemid 23354248)
73. Kribben A, Wieder ED, Li X, van, et al. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase. C Am J Physiol 1993; 265: 939-45.
74. Gardner AM, Vaillancourt RR, Johnson GL. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem 1993; 268: 17896-901. (Pubitemid 23260303)
75. Johnson GL, Gardner AM, Lange-Carter C, Qian NX, Russell M, Winitz S. How does the G protein Gi2 transduce mitogenic signals. J Cell Biochem1994; 54: 415-22. (Pubitemid 24131346)
76. Kavelaars A, Broeke D, Jeurissen F, et al. Activation of human monocytes via a non-neurokinin substance-P receptor that is coupled to G protein calcium phospholipaseD MAP kinase and IL-6 production. J Immunol 1994; 153: 3691-9.
77. Seger R, Biener Y, Feinstein R, Hanoch T, Gazit A, Zick Y. Differential activation of mitogen-activated protein kinase and S6 kinase signaling pathways by 12-O-tetradecanoylphorbol-13-acetate (TPA) and insulin: evidence for involvement of a TPA-stimulated protein-tyrosine kinase. J Biol Chem 1995; 270: 28325-30.
78. Gamou S, Shimizu N. Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett 1995; 357: 161-4.
79. Lander HM, Milbank AJ, Tauras JM, et al. Redox regulation of cell signalling. Nature 1996; 381: 380-1. (Pubitemid 126515840)
80. Chao TS, Byron KL, Lee KM, Villereal M, Rosner MR. Activation of MAP kinases by calcium-dependent and calcium-independent pathways stimulation by thapsigargin and epidermal growth factor. J Biol Chem 1992; 267: 19876-83.
81. Franklin RA, Tordai A, Mazer B, Terada N, Lucas JJ, Gelfand EW. Activation of MAP2-kinase in B lymphocytes by calcium ionophores. J Immunol 1994; 153: 4890-98. (Pubitemid 24356119)
82. Lev S, Moreno H, Martinez R, et al. Protein tyrosine kinase PYK2 involved in Ca(2+)- induced regulation of ion channel and MAP kinase functions. Nature 1995; 376: 737-45.
83. Rosen LB, Ginty DD, Weber MJ, Greenberg ME. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron 1994; 12: 1207-21. (Pubitemid 24186790)
84. Atherfold PA, Norris MS, Robinson PJ, Gelfand EW, Franklin RA. Calcium-induced ERK activation in human T lymphocytes. Mol Immunol 1999; 36: 543-49. (Pubitemid 29386153)
85. Franklin RA, Atherfold PA, McCubrey JA. Calcium-induced ERK activation in human T lymphocytes occurs via p56 (Lck) and CaM-kinase. Mol Immunol 2000; 37: 675-83. (Pubitemid 32112655)
86. Ginnan R, Singer HA. CaM kinase II-dependent activation of tyrosine kinases and ERK1/2 in vascular smooth muscle. Am J Physiol Cell Physiol 2002; 282: C754-C61.
87. Schmitt JM, Wayman GA, Nozaki N, Soderling TR. Calcium activation of ERK mediated by calmodulin kinase I. J Biol Chem 2004; 279: 24064-72. (Pubitemid 38725265)
88. Takahashi H, Ibe M, Nakamura S, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 2002; 30: 94-9. (Pubitemid 36159019)
89. Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005; 152: 37-42.
90. Galcheva-Gargova Z, Derijard B, Wu IH, Davis RJ. An osmosensing signal transduction pathway in mammalian cells. Science1994; 265: 806-8. (Pubitemid 24266144)
91. Conde de la, Rosa L, Schoemaker MH, et al. Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases. J Hepatol 2006; 44: 918-29.
92. Murakami T, Takagi H, Suzuma K, et al. Angiopoietin-1 attenuates H2O2-induced SEK1/JNK phosphorylation through the phosphatidylinositol 3-kinase/Akt pathway in vascular endothelial cells. J Biol Chem 2005; 280: 31841-49. (Pubitemid 41291934)
93. Matsukawa J, Matsuzawa A, Takeda K, Ichijo H. The ASK1-MAP kinase cascades in mammalian stress response. J Biochem 2004; 136: 261-65. (Pubitemid 39545783)
94. Shrivastava A, Aggarwal BB. Antioxidants differentially regulate activation of nuclear factor-kappa B, activator protein-1, c-jun amino-terminal kinases, and apoptosis induced by tumor necrosis factor: evidence that JNK and NF-kappa B activation are not linked to apoptosis. Antioxid Redox Signaling 1999; 1: 181-91. (Pubitemid 129619774)
95. Schmidt KJ, Büning J, Jankowiak C, Lehnert H, Fellermann K. Crohn's Targeted Therapy: Myth or Real Goal? Curr Drug Discov Technol 2009; 6: 290-8.
96. Schieke SM, Briviba K, Klotz LO, et al. Activation pattern of mitogen Activated Protein kinases elicited by peroxynitrite attenuation by selenite supplementation. FEBS Lett 1999; 448: 301-3. (Pubitemid 29168508)
97. Matsuzawa A, Nishitoh H, Tobiume K, Takeda K, Ichijo H. Physiological roles Of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: advanced findings from ASK1 knockout mice. Antioxid Redox Signaling 2002; 4: 415-25. (Pubitemid 34753381)
98. Teramoto H, Coso OA, Miyata H, Igishi T, Miki T, Gutkind JS. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway a role for mixed lineage kinase 3/protein-tyrosine kinase 1 a novel member of the mixed lineage kinase family. J Biol Chem 1996; 271: 27225-28. (Pubitemid 26367270)
99. Kyriakis JM, Avruch J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 1996; 18: 567-77. (Pubitemid 26311096)
100. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 2002; 22: 2871-81 (Pubitemid 34263007)
101. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38 and may mediate activation of CREB. EMBO J 1998; 17: 4426-41. (Pubitemid 28362632)
102. Funding AT, Johansen C, Kragballe K, et al. Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol 2006; 126: 1784-91. (Pubitemid 44086513)
103. Wang F, Lee E, Lowes MA, et al. Prominent production of IL-20 by CD68+/ CD11c+ myeloid-derived cells in psoriasis gene regulation and cellular effects. J Invest Dermatol 2006; 126: 1590-99
104. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994; 76: 253-62. (Pubitemid 24046688)
105. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway recent advances and future challenges. Gene 2002; 285: 1-24. (Pubitemid 34246317)
106. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (Suppl) 2002; 109: S121-31. (Pubitemid 34457857)
107. Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 1603-7. (Pubitemid 19078951)
108. Mertens C, Zhong M, Krishnaraj R, Zou W, Chen X, Darnell JE Jr. Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes Dev 2006; 20: 3372-81. (Pubitemid 44969156)
109. Schindler C, Levy DE, Decker T. JAK-STAT signaling from interferons to cytokines. J Biol Chem 2007; 282: 20059-63.
110. Bouwman RA, Musters RJ, van Beek-Harmsen BJ, de Lange JJ, Lamberts RR, Loer SA, Boer C. Sevoflurane-induced cardio protection depends on PKC alpha activation via production of reactive oxygen species. Br J Anaesth 2007; 99: 639-45. (Pubitemid 351773204)
111. Martelli AM, Evangelisti C, Nyakern M, Manzoli FA. Nuclear protein kinase C. Biochim Biophys Acta 2006; 1761: 542-51.
112. Moscat J, Rennert P, Diaz-Meco MT. PKC zeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways. Cell Death Differ 2006; 13: 702-11.
113. Zhao Y, Fishelevich R, Petrali JP, et al. Activation of keratinocyte protein kinase C zeta in psoriasis plaques. J Invest Dermatol 2008; 128: 2190-97.
114. Duran A, Diaz-Meco MT, Moscat J. Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J 2003; 22: 3910-8. (Pubitemid 36975717)
115. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-9. (Pubitemid 32121803)
116. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007; 2007: 78454.
117. Yildirim M, Inaloz HS, Baysal V, Delibas N. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 34-6. (Pubitemid 36163651)
118. Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J 2003; 44: 24-6. (Pubitemid 36322510)
119. Drewa G, Krzyzynska-Malinowska E, Wozniak A, et al. Activity of superoxide dismutase and catalase and the level of lipid peroxidation products reactive with TBA in patients with psoriasis. Med Sci Monit 2002; 8: BR338-BR43.
120. Kokcam I, Naziroglu M. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. Clin Chim Acta 1999; 289: 23-31. (Pubitemid 29505196)
121. Romanowska M, al Yacoub N, Seidel H, et al. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparinbinding EGF-like growth factor. J Invest Dermatol 2008; 128: 110- 24.
122. Schroeder WT, Thacher SM, Stewart-Galetka S, et al. Type I kerantinocyte transglutaminase: expression in human skin and psoriasis. J Invest Dermatol 1992; 99: 27-34.
123. Gilhar A, Ullmann Y, Kerner H, et al. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 2002; 119: 384-91. (Pubitemid 35001948)
124. Seung NR, Park EJ, Kim CW, et al. Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4 and T-cell receptor gammadelta in plaque and guttate psoriasis. J Cutan Pathol 2007; 34: 903-11. (Pubitemid 350132007)
125. Curry JL, Qin JZ, Bonish B, et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003; 127: 178-86. (Pubitemid 36231763)
126. Lucke T, Choudhry R, Thom R, Selmer IS, Burden AD, Hodgins MB. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis vaginal epithelium and buccal epithelium. J Invest Dermatol 1999; 112: 354-61. (Pubitemid 29125113)
127. Lemaitre G, Sivan V, Lamartine J, et al. Connexin 30 a new marker of hyperproliferative epidermis. Br J Dermatol 2006; 155: 844-6. (Pubitemid 44352574)
128. Nanney LB, Stoscheck CM, Magid M, King LE Jr. Altered [125i]epidermal growth factor binding and receptor distribution in psoriasis. Biull Eksp Biol Med 1993; 115: 618-20.
129. Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991; 138: 129-40.
130. Blessing M, Schirmacher P, Kaiser S. Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J Cell Biol 1996; 135: 227-39. (Pubitemid 26337750)
131. Grove T, Mulfinger L. The pathogenesis of psoriasis: biochemical aspects. J Young Invest 2001; 4.
132. Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997; 151: 1321-9. (Pubitemid 27479762)
133. Batinac T, Zamolo G, Hadzisejdic I, et al. Expression of Bcl-2 family proteins in psoriasis. Croat Med J 2007; 4: 319-26. (Pubitemid 47035681)
134. Wrone-Smith T, Johnson T, Nelson B, et al. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995; 146: 1079-88.
135. Tomkova H, Fujimoto W, Arata J. Expression of bcl-2 antagonist bak in inflammatory and neoplastic skin diseases. Br J Dermatol 1997; 137: 703-8. (Pubitemid 27496185)
136. Tomkova H, Fujimoto W, Arata J. Expression of the bcl-2 homologue Bax in normal human skin, psoriasis vulgaris and non-melanoma skin cancers. Eur J Dermatol 1998; 8: 256-60. (Pubitemid 28281453)
137. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-28. (Pubitemid 38903524)
138. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferonalpha production. J Exp Med 2005; 202: 135-43 (Pubitemid 41002916)
139. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22 a TH17 cytokine mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51. (Pubitemid 46232884)
140. Chien AJ, Presland RB, Kuechle MK. Processing of native caspase-14 occurs at an atypical cleavage site in normal epidermal differentiation. Biochem Biophys Res Commun 2002; 296: 911-7.
141. Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM. Caspase-14 is a novel developmentally regulated protease. J Biol Chem 1998; 273: 29648-53. (Pubitemid 28509974)
142. Van de Craen M, Van Loo G, Pype S, et al. Identification of a new caspase homologue: caspase-14. Cell Death Differ 1998; 5: 838-46. (Pubitemid 28484394)
143. Lippens S, VandenBroecke C, Van Damme E, Tschachler E, Vandenabeele P, Declercq W. Caspase-14 is expressed in the epidermis the choroid plexus the retinal pigment epithelium and thymic Hassall's bodies. Cell Death Differ 2003; 10: 257-9. (Pubitemid 36553468)
144. Lippens S, Kockx M, Knaapen M, et al. Epidermal differentiation does not involve the pro-apoptotic executioner caspases but is associated with caspase-14 induction and processing. Cell Death Differ 2000; 7: 1218-24. (Pubitemid 32042229)
145. D'Aura Swanson C, Paniagua RT, Lindstrom TM, Robinson WH. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 317-24.
146. Eklund KK, Lindstedt K, Sandler C, et al. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol 2008; 14: 294-6.
147. Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006; 116: 2633-42. (Pubitemid 44511627)
148. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34. (Pubitemid 35425239)
149. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 55 48-57.
150. Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008; 128: 1365-74. (Pubitemid 351693180)
151. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-87. (Pubitemid 41058349)
152. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-98.
153. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases to be or not to be. Nat Immunol 2009; 10: 356-60.
154. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938-42.
155. Gilhar A, Ullmann Y, Kerner H, et al. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 2002; 119: 384-91. (Pubitemid 35001948)
156. Hegemann L, Hatzelmann A, Grewig S, Schmidt BH. Potent antagonism of calmodulin activity in vitro, but lack of antiproliferative effects on keratinocytes by the novel leukotriene biosynthesis inhibitor MK-886. Br J Dermatol1995; 133: 41-7.
157. Mayser P, Grimm H, Grimminger F. N-3 fatty acids in psoriasis. Br J Nutrition 2002; 87(Suppl): 577-82.
158. Mommers JM, Van Rossum MM, Kooijmans-Otero ME, Parker GL, van de Kerkhof PC. VML 295 (LY-293111) a novel LTB4 antagonist is not effective in the prevention of relapse in psoriasis. Br J Dermatol 2000; 142: 259-66. (Pubitemid 30117695)
159. Mozzanica N, Cattaneo A, Vignati G, Finzi A. Plasma neuropeptide levels in psoriasis. Acta Dermatovenereol 1994; 186; 67-8. (Pubitemid 24208157)
160. Naukkarinen A, Järvikallio A, Lakkakorpi J, Harvima IT, Harvima RJ, Horsmanheimo M. Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol 1996; 180: 200- 5.
161. Steinhoff M, Ständer S, Seeliger S, Ansel JC, Schmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003; 139: 1479-88. (Pubitemid 37433137)
162. Saraceno R, Kleyn CE, Terenghi G, Griffiths CE. The role of neuropeptides in psoriasis. Br J Dermatol 2006; 155: 876-82. (Pubitemid 44564493)
163. Raychaudhuri SP, Jiang WY, Farber EM. Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol 1998; 78: 84-6. (Pubitemid 28153332)
164. Elder JT, Henseler T, Christophers E, Voorhees JJ, Nair RP. Review of genes and antigens the inheritance of psoriasis. J Invest Dermatol 1994; 103: 150S-3S. (Pubitemid 24348793)
165. Elder JT, Nair RP, Henseler T, et al. The genetics of psoriasis 2001 the odyssey continues. Arch Dermatol 2001; 137: 1447-54. (Pubitemid 33069391)
166. Farber EM, Nall L, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974; 109: 207-11.
167. Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE. Psoriasis in monozygotic twins variations in expression in individuals with identical genetic constitution. Acta Dermatol 1982; 62: 229- 36.
168. Henseler T, Christophers E. Psoriasis of early and late onset characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13(3): 450-6. (Pubitemid 15016489)
169. Swanbeck G, Inerot A, Martinsson T, Wahlström J. A population genetic study of psoriasis. Br J Dermatol 1994; 131: 32-9. (Pubitemid 24234285)
170. Guedjonsson JE, Karason A, Antonsdottir AA, et al. HLA-CW6-positive and HLA-CW6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118: 362-5. (Pubitemid 34158494)
171. Gottlieb AB, Krueger JG. HLA region genes and immune activation in the pathogenesis of psoriasis. Arch Dermatol 1990; 126: 1083-6. (Pubitemid 20233186)
172. Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M. Psoriasis and HLA-Cw6.Br J Dermatol 1980; 102: 179-84. (Pubitemid 10148338)
173. Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol 2000; 143: 1177-82. (Pubitemid 32052752)
174. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome wide scan. Hum Mol Genet 1997; 6: 1349-56. (Pubitemid 27351077)
175. Matthews D, Fry L, Powles A, et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet 1996; 14: 231-3. (Pubitemid 26338812)
176. Speckman RA, Daw J, Helms C, et al. Novel cluster of immunoglobulin superfamily members mapping to a region of 17q25.1 linked to psoriasis susceptibility. Hum Genet 2002; 112: 34-41. (Pubitemid 36869113)
177. Enlund F, Samuelsson L, Enerback C, et al. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur J Hum Genet 1999; 7: 783-90. (Pubitemid 29516237)
178. Capon F, Novelli G, Semprini S, et al. Searching for psoriasis susceptibility genes in Italy Genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 1999; 112: 52-5.
179. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6: 813-20. (Pubitemid 27199077)
180. Enlund F, Samuelsson L, Enerback C, et al. Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families confirmation of linkage to chromosome 6p (HLA region) and to 17q, but not to 4q. Hum Hered 1999; 49: 2-8. (Pubitemid 29050288)
181. Nair RP, Stuart P, Henseler T, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLAC. Am J Hum Genet 2000; 66: 1833-44. (Pubitemid 30480090)
182. Oka A, Tamiya G, Tomizawa M, et al. Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum Mol Genet 1999; 8: 2165-70. (Pubitemid 29525330)
183. Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264: 1141-5. (Pubitemid 24210675)
184. Lee YA, Roschendorf F, Windemuth C, et al. Genome wide scan in German families reveals evidence for a novel psoriasissusceptibility locus on chromosome 19p13. Am J Hum Genet 2000; 67: 1020-4.
185. Portugal M, Barak V, Ginsburg I, Kohen R. Interplay among oxidants, antioxidants, and cytokines in skin disorders present status and future considerations. Biomed Pharmacother 2007; 61: 412-22. (Pubitemid 47239346)
186. Kunz, Manfred. Current Treatment of Psoriasis with Biologics. Curr Drug Discov Technol 2009; 6: 231-40.
187. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem1995; 64: 97-112.
188. Thérond P, Gerbaud P, Dimon S, Anderson WB, Evain-Broin D, Raynaud F. Antioxidant enzymes in psoriatic fibroblasts and erythrocytes. J Invest Dermatol 1996; 106: 1325-8. (Pubitemid 26195853)
189. Yildirim M, Inaloz HS, Baysal V, Delibas N. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 34-6. (Pubitemid 36163651)
190. Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med 1999; 27: 951-65. (Pubitemid 29507469)
191. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000; 267: 6102-9.
192. Schallreuter KU, Wood JM. Thioredoxin reductase, its role in epidermal redox status. J Photochem Photobiol 2001; 64: 179-84. (Pubitemid 33133670)
193. Foss FM. DAB (389) IL-2 (denileukin diftitox, ONTAK) a new fusion protein technology. Clin Lymphoma 2000; 1(Suppl. 1): S27-31.
194. Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43: 448-58. (Pubitemid 30666736)
195. Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol 2000; 143: 1121-2.
196. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 2000; 25: 195-7. (Pubitemid 30340544)
197. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073-80. (Pubitemid 37548113)
198. Da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept an immunomodulatory recombinant LFA-3/IgG1 fusion protein induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2 (p) cells. J Immunol 2002; 168: 4462-71. (Pubitemid 34441348)
199. Krueger G. Clinical response to alefacept results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17(Suppl. 2): 17-24.
200. Langley R, Roenigk H, McCall C. Phase I results of intravenous MEDI-507 an anti-T-cell antibody for the treatment of psoriasis. J Invest Dermatol 2001; 117: 817.
201. Kimball AB, Kawamura T, Tejura K, et al. Clinical and immunologic assessment of patients with psoriasis in a randomized double-blind placebo-controlled trial using recombinant human interleukin -10. Arch Dermatol 2002; 138: 1341-6.
202. Chen DM, Gordon K, Leonardi C, et al. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis preliminary findings from a 12 week dose ranging trial. J Am Acad Dermatol 2004; 50(Pt II): PS 491.
203. Trepicchio WL, Bozza M, Pedneault G, Dorner AJ. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996; 157: 3627-34. (Pubitemid 126449177)
204. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis a randomized double-blind placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42. (Pubitemid 39278071)
205. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22. (Pubitemid 37448924)
206. Zhou X, Krueger JG, Kao MC. Abgenix discontinues treatment after disappointing psoriasis study results. East Bay Business Times 2002.
207. Griffiths CE, Strober BE, Van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
208. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT- 874, a fully human interleukin 12/23 monoclonal antibody in the treatment of moderate to severe chronic plaque psoriasis results of a randomized placebo-controlled phase 2 trials. Arch Dermatol 2008; 144: 200-7. (Pubitemid 351287002)
209. Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNFa monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: Preliminary results from a double-blind, placebo-controlled trial. Jean-Paul Ortonnne, University of Nice-Sophia Antipolis, Nice, France; Chantal Tasset.
210. Kim HS, Cho IH, Kim JE, Shin, et al. Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radic Biol Med 2008; 45: 950-63.
211. Nelson KC, Carlson JL, Newman ML, et al. Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest Ophthalmol Visual Sci 1999; 40: 1927-35. (Pubitemid 29365154)
212. Burton G, Ingold K. Mechanisms of Antioxidant Action Preventive and Chain- Breaking Antioxidants. CRC press, Boca Raton; 1989.
213. Becker BF, Reinholz N, Leipert B, Raschke P, Permanetter B, Gerlach E. Role of uric acid as an endogenous radical scavenger and antioxidant. Chest 1991; 100: 176S-81S.
214. Varani J, Lateef H, Fay K, Elder JT. Antagonism of epidermal growth factor receptor tyrosine kinase ameliorates the psoriatic phenotype in organ-cultured skin. Skin Pharmacol Physiol 2005; 18: 123-31. (Pubitemid 40868668)
215. Keshtgarpour M, Dudek AZ. SU-011248 a vascular endothelial growth factor receptor-tyrosine kinase inhibitor controls chronic psoriasis. Transl Res 2007; 149: 103-6. (Pubitemid 46275576)
216. Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006; 116: 2633-42. (Pubitemid 44511627)
217. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22. (Pubitemid 46106205)
218. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumor. Br J Dermatol 2002; 147: 406-7.
219. Cameron D, Stein S. Drug insight intracellular inhibitors of HER2 clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 2008; 5: 512-20